Is ACADIA's Raised Guidance and Acquisition Plans Reshaping the Investment Narrative for ACAD? [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
million, alongside a raised full-year revenue outlook and plans to pursue acquisitions supported by a strong balance sheet. The company highlighted significant sales growth for its marketed drugs DAYBUE and NUPLAZID, as well as progress across its clinical pipeline and upcoming readouts for 2026 and 2027. We'll now evaluate how ACADIA's better-than-expected results and increased guidance could influence its future earnings trajectory and risk profile. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave ACADIA Pharmaceuticals Investment Narrative Recap To be comfortable owning ACADIA Pharmaceuticals, investors should have conviction in the company's ability to deliver consistent growth from its CNS and rare disease portfolio, while expanding its pipeline beyond NUPLAZID dependence. The raised full-year guidance and strong Q3 results reinforce management's progress, yet do not meaningfully shift the primary short-term catalyst,
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]Seeking Alpha
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $29.00 price target on by analysts at Mizuho.MarketBeat
- Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- ACAD's page on the SEC website